This is not the most recent version of the article. View current version (11 MAY 2011)

Intervention Protocol

Prophylactic corticosteroids for cardiopulmonary bypass in adults

  1. Jan M Dieleman1,*,
  2. Judith van Paassen2,
  3. Diederik van Dijk3,
  4. Sesmu M Arbous2,
  5. Cor J Kalkman1,
  6. Jan P Vandenbroucke4,
  7. Geert J van der Heijden5,
  8. Olaf M Dekkers4

Editorial Group: Cochrane Heart Group

Published Online: 20 JAN 2010

DOI: 10.1002/14651858.CD005566.pub2


How to Cite

Dieleman JM, van Paassen J, van Dijk D, Arbous SM, Kalkman CJ, Vandenbroucke JP, van der Heijden GJ, Dekkers OM. Prophylactic corticosteroids for cardiopulmonary bypass in adults (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD005566. DOI: 10.1002/14651858.CD005566.pub2.

Author Information

  1. 1

    University Medical Center Utrecht, Division of Perioperative Care & Emergency Medicine, Utrecht, Netherlands

  2. 2

    Leiden University Medical Center, Department of Intensive Care, Leiden, Netherlands

  3. 3

    University Medical Center Utrecht, Department of Intensive Care, Utrecht, Netherlands

  4. 4

    Leiden University Medical Center, Department of Clinical Epidemiology, Leiden, Netherlands

  5. 5

    University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands

*Jan M Dieleman, Division of Perioperative Care & Emergency Medicine, University Medical Center Utrecht, PO Box 85500, mailstop: Q04.2.313, Utrecht, 3508 GA, Netherlands. s.dieleman@umcutrecht.nl.

Publication History

  1. Publication Status: Amended to reflect a change in scope (see 'What's new')
  2. Published Online: 20 JAN 2010

SEARCH

This is not the most recent version of the article. View current version (11 MAY 2011)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To estimate the effect of corticosteroid use for cardiopulmonary bypass on:

a) a composite end-point of mortality, myocardial infarction and pulmonary complications (including pulmonary oedema and/or infection);

b) the other relevant outcomes such as other complications, including prolonged mechanical ventilation and stroke.